Encompass Health (EHC) Q2 2026 Earnings Call Transcript
Encompass Health (EHC) reported Q2 2026 net operating revenue of $1.597B (+9.6% YoY), adjusted EBITDA of $348M (+9.2%), and adjusted EPS of $1.55 (+10.7%). Full-year 2026 guidance was raised: revenue $6.41B-$6.49B, adjusted EBITDA $1.365B-$1.395B, adjusted EPS $6.02-$6.25. The company also increased its $1B share repurchase authorization.
How this was made
The 30-second read
Why it matters
Management reported stronger discharge volumes, higher net revenue per discharge, improved labor metrics, and raised 2026 guidance, while also citing ongoing Medicare Advantage pre-authorization denials as a continuing headwind.
Market read
Traders can update models immediately using the raised 2026 revenue, EBITDA, and EPS ranges, plus the $1B buyback authorization and updated labor and occupancy KPIs.
What to watch
The CMS 2027 IRF final rule is an estimate (2.3% net revenue per discharge for Medicare patients starting Oct. 1, 2026), and scaling the admit-and-appeal pilot may not replicate uniformly across the portfolio.
Background
This is Encompass Health’s Q2 2026 earnings call transcript summary, including operating KPIs, full-year guidance updates, and capital allocation commentary.
Ticker impact
Encompass Health raised 2026 revenue guidance to $6.41B-$6.49B and adjusted EBITDA to $1.365B-$1.395B, plus increased EPS outlook.
Near-term bias higher as traders price the raised 2026 targets and buyback authorization; downside risk if MA pre-authorization denials worsen.
The article provides multiple forward-looking datapoints (raised revenue, EBITDA, EPS guidance; CMS 2027 IRF rule estimate; expanded bed pipeline; higher occupancy) that can drive revisions, but it also flags ongoing MA denial friction and provider tax adjustments as offsets.
Market effects
Reinforces demand strength and labor efficiency themes in post-acute inpatient rehab, potentially supporting sentiment for IRF operators.
North Carolina development focus and repeal of Certificate of Need laws may shift competitive expectations for IRF capacity in that state.
Limited direct global linkage; primarily US Medicare reimbursement and labor-cost dynamics.
Counterpoint
Raised guidance may be partially offset by Medicare Advantage pre-authorization denials and provider tax benefit normalization, so upside could be less durable than it appears.
Key entities
- companyEncompass Health Corporation
IRF operator reporting Q2 2026 results and raising full-year 2026 guidance, with increased share repurchase authorization.
- executiveMark Tarr
CEO who discussed guidance, quality metrics, and North Carolina expansion strategy.
- executiveDouglas Coltharp
Speaker highlighting Medicare Advantage denial challenges and provider tax impact adjustments.
- regulatorCMS
Sets Medicare reimbursement rules; referenced via the CMS 2027 IRF final rule estimate.
